ERBB2 and gastric cancer: The ToGA (Trastuzumab for Gastric Cancer) trail demonstrated that anti-HER2 monoclonal antibody Trastuzumab with chemotherapy prolonged survival of HER2 positive advanced gastric cancer (AGC) patients (Bang et al., 2010).